UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000020719
Receipt number R000023906
Scientific Title Cohort study of immune-checkpoint-inhibitor antibody treatment in non-small-cell lung cancer
Date of disclosure of the study information 2016/01/24
Last modified on 2017/07/31 22:09:14

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Cohort study of immune-checkpoint-inhibitor antibody treatment in non-small-cell lung cancer

Acronym

Immune-Checkpoint-Inhibitor Cohort Study

Scientific Title

Cohort study of immune-checkpoint-inhibitor antibody treatment in non-small-cell lung cancer

Scientific Title:Acronym

Immune-Checkpoint-Inhibitor Cohort Study

Region

Japan


Condition

Condition

non-small-cell lung cancer

Classification by specialty

Pneumology Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

Search for biomarkers to reveal the enabled subgroup immune-checkpoint- inhibitor

Basic objectives2

Others

Basic objectives -Others

Search of biomarkers to predict the immune related adverse effect (irAE) by the immune-checkpoint-inhibitor

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

analysis of peripheral blood mononuclear cell(PBMC)

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients who are scheduled for administration of nivolumab
2) With written informed consent

Key exclusion criteria

1) Having psychological disorder
2) In addition, the primary doctor judging inappropriate for entry

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ou Yamaguchi

Organization

Saitama Medical University International Medical Center

Division name

respiratory medicine

Zip code


Address

Hidaka city, Saitama

TEL

042-984-4111

Email

ouyamagu@saitama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Ou Yamaguchi

Organization

Saitama Medical University International Medical Center

Division name

respiratory medicine

Zip code


Address

Hidaka city, Saitama

TEL

042-984-4111

Homepage URL


Email

ouyamagu@saitama-med.ac.jp


Sponsor or person

Institute

Saitama Medical University International Medical Center

Institute

Department

Personal name



Funding Source

Organization

Saitama medical university international medical center

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 01 Month 24 Day


Related information

URL releasing protocol


Publication of results

Partially published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2016 Year 01 Month 24 Day

Date of IRB


Anticipated trial start date

2016 Year 02 Month 15 Day

Last follow-up date

2018 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

prpspective cohort study of immune-checkpoint-inhibitor treatment in non-small-cell lung cancer


Management information

Registered date

2016 Year 01 Month 24 Day

Last modified on

2017 Year 07 Month 31 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000023906


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name